Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kyverna Therapeutics, Inc. - Common Stock (NQ:KYTX)

6.970 +0.220 (+3.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kyverna Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your
From Grabar Law Office
Via GlobeNewswire
ALERT: Grabar Law Office Investigates Claims for Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); and Virtu Financial, Inc. (NASDAQ: VIRT)
From Grabar Law Office
Via GlobeNewswire
Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is
From Grabar Law Office
Via GlobeNewswire
Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your
From Grabar Law Office
Via GlobeNewswire
Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your
From Grabar Law Office
Via GlobeNewswire
Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
Deadline Soon: Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
KYTX Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Investors of Filing Deadline in Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
KYTX Deadline in 3 Days: Kessler Topaz Meltzer &amp; Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Investors of Filing Deadline in Class Action Lawsuit
RADNOR, PA - February 3, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna... 
Via TheNewswire.com
Topics Lawsuit
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kyverna, Sun Communities, DMC Global, and Marqeta and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
KYVERNA THERAPEUTICS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX
From Kahn Swick & Foti, LLC
Via Business Wire
KYTX Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Investors of Filing Deadline in Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
KYTX Deadline in 4 Days: Kessler Topaz Meltzer &amp; Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Investors of Filing Deadline in Class Action Lawsuit
RADNOR, PA - February 3, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna... 
Via TheNewswire.com
Topics Initial Public Offering Lawsuit
KYVERNA THERAPEUTICS, INC. (NASDAQ: KYTX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Kyverna Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
KYTX Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Investors of Filing Deadline in Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
KYTX Deadline in 5 Days: Kessler Topaz Meltzer &amp; Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Investors of Filing Deadline in Class Action Lawsuit
RADNOR, PA - February 2, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna... 
Via TheNewswire.com
Topics Initial Public Offering Lawsuit
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.